Oncology health tech firm Flatiron Health will use Massive Bio’s patient database to identify and recruit participants for clinical trials, the Roche Group affiliate announced in an April 7 release.

Flatiron’s presence at ESMO AI demonstrates deep methodological expertise in AI and machine learning applications across global markets and showcases the possibility of trustworthy LLM-extracted ...

Health tech company Flatiron Health, an independent affiliate of the Roche Group, is expanding the reach of its clinical data capture tool through a pact with NRG Oncology. NRG Oncology is a research ...

Flatiron’s research at this year’s conference highlights the ability of scalable, high-quality real-world oncology data and novel rigorous approaches for health outcomes research to support both ...

Outgoing CEO Carolyn Starrett to transition as Senior Advisor following a tenure marked by global growth and data leadership “I’m honored to step into this role,” said Hubbard. “With deep roots in ...

Adaptive Biotechnologies Corporation and Flatiron Health have announced the integration of Adaptive's clonoSEQ® test for measurable residual disease (MRD) assessment into Flatiron's OncoEMR® ...

Oncology-focused digital health company Flatiron Health announced it entered into a strategic partnership with Massive Bio, a company that helps cancer patients find and enroll in clinical trials.

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including three accepted ...

DeepScribe, an AI-enabled clinical documentation tool for healthcare providers, is partnering with oncology-focused digital health company Flatiron Health to bring DeepScribe's AI documentation to ...

Flatiron’s LLM-enabled data extraction and rigorous validation have unlocked 505,000 patients with hematologic malignances, including rare patient cohorts with rich clinical detail at unprecedented ...